Psychedelic-Assisted Therapy

Practice

Something people do: ritual, method, exercise, ceremony, modality, or reading.

The supervised clinical use of a psychedelic or dissociative drug inside a course of preparation, dosing sessions, psychotherapy, and integration.

Psychedelic-assisted therapy is the clinical face of the modern psychedelic revival. It borrows the central insight of older psychedelic research, underground guiding, and plant-medicine ceremony: the drug session is not treated as a stand-alone event. The person prepares, enters the altered state in a held setting, and then works afterward to understand what happened. The difference is the container. This is therapy room rather than retreat hut, trial site rather than festival, treatment protocol rather than private experiment.

What the practice is

Psychedelic-assisted therapy is a structured intervention in which a psychoactive drug is given as part of psychotherapy or psychological support. The protocol usually has three phases: preparation, one or more supervised medicine sessions, and integration afterward. The substance changes the state; the therapy gives the state a frame.

The field uses “psychedelic” loosely. Psilocybin, LSD, and DMT are classic psychedelics, acting mainly through serotonin 5-HT2A receptor systems. MDMA is usually classed as an empathogen or entactogen rather than a classic psychedelic. Ketamine and esketamine are dissociatives, acting primarily through glutamate pathways. In practice, all four sit in the same public conversation because they share the same promise: a time-limited altered state, held by clinicians or guides, may let a person meet material that ordinary talk therapy has not reached.

As of mid-2026, the regulatory status is uneven. Esketamine nasal spray is FDA-approved for treatment-resistant depression in adults, as monotherapy or with an oral antidepressant, and IV or intramuscular ketamine is widely offered off-label in clinics. MDMA-assisted therapy for PTSD remains unapproved in the United States after the FDA issued a complete response letter to Lykos in August 2024. Psilocybin-assisted therapy has trial data and priority-review movement, but it is still under review rather than broadly approved.

What the practitioner does

The practitioner is usually a clinician, therapist, psychiatrist, psychologist, trained facilitator, or supervised trial staff member. In the most formal model, a prescribing clinician manages the drug and a therapy team manages preparation, support, and integration. Many protocols use two therapists or guides in the room during dosing.

Preparation is not small talk. The practitioner takes history, explains the session frame, builds trust, clarifies intention, and helps the participant understand what may happen. The point is not to script the experience. It is to create enough relational ground that the participant can surrender some control without feeling abandoned.

During dosing, the practitioner usually says less than a normal therapist would. The room is arranged for inward attention: couch or bed, eyeshades, music, monitoring where the protocol requires it, and enough quiet for the experience to unfold. The practitioner may offer reassurance, ask a short question, or help when speech becomes necessary. Much of the work is skilled restraint.

Integration happens after the acute drug effect has passed. The practitioner helps the participant put language around images, memories, emotions, insights, or bodily experiences, then asks what ordinary-life change follows. Without integration, the session can become an isolated episode. With integration, it may become material for therapy, relationship repair, grief work, creative direction, spiritual practice, or medical decision-making.

What the participant does

The participant enters as both client and experiencer. Before dosing, she tells the truth about her history, medications, hopes, fears, and prior altered-state experience. She also begins the psychological work of giving the session a question without turning that question into a demand.

During dosing, the participant’s task is usually to turn inward. In many protocols she wears eyeshades and listens to a carefully sequenced playlist. She may speak, cry, shake, laugh, remember, become quiet, or lose the desire to narrate at all. MDMA sessions often remain more verbal and relational. Psilocybin sessions tend to be more visionary. Ketamine sessions can feel dreamlike, detached, or spacious.

The participant’s hardest work often comes later. A session may produce an encounter with grief, shame, forgiveness, childhood memory, bodily fear, or a sense of contact with something larger than the personal self. The experience doesn’t explain itself. The practice asks the participant to bring that material back into ordinary life.

Setting, sequence, and materials

The setting is part of the method. Clinical rooms are often softened so they don’t feel like ordinary medical offices: dim light, blankets, art, a couch, music, and privacy for crying or silence. Trial settings add protocol discipline: inclusion and exclusion criteria, outcome measures, medication rules, staff training, and documentation.

A typical sequence begins with screening and preparation. The dosing day is longer than a normal therapy session, often several hours, with staff present throughout the acute drug effect. Afterward the participant rests, returns for integration sessions, and may have additional dosing sessions depending on the protocol. MDMA trials used several medicine sessions across months. Psilocybin trials often use one or two high-dose sessions. Esketamine follows a repeated dosing schedule under direct healthcare supervision.

The materials are the drug, the room, the music, the therapeutic relationship, the participant’s body, and the record of what happened: clinical notes, a journal, drawings, voice memos, or a few sentences that seemed to carry the whole session.

Claimed mechanism

The biomedical claim differs by substance. Classic psychedelics are studied for their effects on serotonin 5-HT2A signaling, perception, emotional processing, and neural flexibility. MDMA increases serotonin, norepinephrine, dopamine, and trust or closeness that may make trauma processing more tolerable. Ketamine and esketamine affect NMDA-glutamate systems and can produce rapid shifts in depressive symptoms for some patients.

The therapeutic claim is more experiential. The altered state may loosen rigid narratives, reduce defensive control, make emotion accessible, and let the participant encounter memory or meaning from a new angle. Practitioners often describe a window in which therapy can move. The drug doesn’t do the work by itself; the session opens a condition in which the work can happen differently.

The evidence picture is promising and unsettled. MDMA phase 3 trials reported strong PTSD symptom reductions, yet the FDA later found unresolved questions about durability, bias, adverse-event collection, and how much the psychotherapy contributed. Psilocybin depression studies have reported rapid antidepressant effects with psychological support, while larger trials and regulatory review continue. Esketamine is the clearest clinical case because it is approved, labeled, and administered under a restricted program.

Claimed benefits

The claimed benefits cluster around depression, PTSD, end-of-life distress, addiction, grief, and stuck therapeutic material. Participants often say the session let them approach something they had avoided for years. Some describe a sense of self-compassion that ordinary effort could not produce. Others describe a symbolic or spiritual encounter: a dead parent, a field of light, a life review, a child self, an animal, a divine presence, or a feeling that the world is once again alive.

Clinical language and spiritual language often describe the same session differently. A psychiatrist may speak of reduced depressive symptoms or fear extinction. A participant may say she met grief and was allowed to live. A guide may speak of surrender, trust, or the intelligence of the medicine. The practice sits where those vocabularies meet.

Training and certification norms

Training is not standardized across the whole field. FDA-regulated trials train staff to a specific protocol. Esketamine clinics work through licensed prescribers and certified treatment settings. Ketamine-assisted psychotherapy varies much more: some providers are psychiatrists or anesthesiologists working with therapists, while others come from coaching, psychedelic-facilitation, or underground-guide backgrounds.

Several organizations now offer psychedelic-therapy certificates, but a certificate is not the same thing as licensure. The more credible programs teach ethics, screening, scope of practice, trauma sensitivity, pharmacology, consent, boundaries, integration, and referral. The less credible ones sell the romance of the psychedelic guide without enough clinical accountability. The practical question is what license, training, supervision, and accountability stand behind the credential.

Psychedelic-assisted therapy belongs among the somatic and wellness modalities of The Ways, next to microdosing, breathwork, and other practices that deliberately alter state. It contrasts with Ayahuasca, where the container is ceremonial, plant-lineage, and often religious.

The experiences it can occasion connect it to ego death and spiritual awakening. Its medical, psychological, provider, and legal risks belong in Psychedelic Harms, where enthusiasm is held against screening, destabilization, adverse events, and practitioner accountability.

Sources

U.S. Food and Drug Administration, SPRAVATO (esketamine) nasal spray prescribing information (revised January 2025) — current esketamine indications, supervised administration, monitoring, and REMS status.
U.S. Food and Drug Administration, Complete Response Letter for NDA 215455, midomafetamine capsules (August 8, 2024) — FDA response to Lykos’s MDMA-assisted therapy application.
U.S. Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations (2023 guidance) — study design, monitoring, abuse-potential assessment, and adequate clinical investigations for psychedelic-drug trials.
U.S. Food and Drug Administration, “FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order” (April 24, 2026) — current FDA statement that psilocybin programs are receiving priority-review support while remaining under review.
Jennifer M. Mitchell et al., “MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial” (Nature Medicine, 2023) — the second phase 3 MDMA-assisted therapy trial.
Roland R. Griffiths, Alan K. Davis, Frederick S. Barrett, et al., “Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder” (JAMA Psychiatry, 2020) — randomized clinical trial of psilocybin-assisted therapy with psychological support.
Charles L. Raison et al., “Single-Dose Psilocybin Treatment for Major Depressive Disorder” (JAMA, 2023) — phase 2 trial of psilocybin with psychological support.
Robin Carhart-Harris et al., “Trial of Psilocybin versus Escitalopram for Depression” (New England Journal of Medicine, 2021) — comparative depression trial showing why psilocybin evidence is serious but not settled.

Keyboard shortcuts